key: cord-0800046-yathfjlz
authors: Sorbello, Massimiliano; El-Boghdadly, Kariem; Petrini, Flavia
title: Airway Management in COVID-19: In the Den of the Beast
date: 2020-04-22
journal: Anesth Analg
DOI: 10.1213/ane.0000000000004883
sha: a7d66beaa64978f88c81c7aefe1e9b693ba1716d
doc_id: 800046
cord_uid: yathfjlz

nan

To the Editor W e read with great interest the editorial by Dr Orser. 1 We thank her for highlighting some critical concepts for clinicians dealing with the current coronavirus disease 2019 (COVID-19) crisis and congratulate her for the clarity and conciseness in delivering an important message. We would like to support her principles further with some considerations for clinicians.

The first point is that COVID-19 appears to have a different clinical and epidemiological profile than severe acute respiratory syndrome (SARS). Despite being from similar coronavirus families, and the case fatality rate of SARS appears higher, the R 0 of the SARS coronavirus 2 (SARS-CoV-2) that causes COVID-19 is greater. This results in a greater spread and a higher raw number of deaths. 2 In Italy, the case fatality rate has been high, with 16,654 deaths out of 136,110 positive cases as of April 9, 2020, with health care professionals being at highest risk for infection, accounting for around 10% of positive cases (Istituto Superiore di Sanità; https://www.epicentro.iss.it/coronavirus/ sars-cov-2-sorveglianza-dati).

The transmissibility of SARS-CoV-2 might have been underestimated by many. In Italy, there is a high rate of health care worker-related infection leading to self-isolation, hospitalization, and critical care admission, with its consequences on health care delivery and the well-being of the workforce. One of the key concerns with the SARS-CoV-2 virus is that the modality for transmission remains uncertain, as "airborne diffusion cannot be ruled out at this stage." 3 Compounding this uncertainty is the potential for the virus to variably survive on different surfaces and a lack of vaccine or specific treatment. 2 There are some suggestions that the virus should be treated on bio-safety level 4, 4 which is obviously not feasible in pandemic settings.

However, we advocate maximizing the level of personal protective equipment (PPE) during aerosolgenerating procedures (AGPs), such as tracheal intubation and noninvasive ventilation and high-flow nasal oxygen use. 2 The use of N95 respirators, which offers a similar degree of protection as filtering face piece (FFP)2 respirators, 2 with some data suggesting that they are in fact equivalent to surgical facemasks. 5 Recommendations in Italy 2 and the United Kingdom 6 are for the use of FFP3 or N99 masks, which is different from North American recommendations. Ideally, powered air-purifying respirators (PAPRs) should be used. 2, 4 Additionally, we advocate the use of goggles, a visor/face shield, double (or triple) gloving, and ideally a full body suit.

We completely agree with Dr Orser's 1 recommendations for training in PPE donning and doffing, harnessing teamwork, and leadership by the most expert airway manager. Further, we also highlight the importance of planning (communication in PPE could be particularly challenging) and of hemodynamic optimization, if time is available. We strongly advocate for the conduct of rapid sequence intubation with full-dose neuromuscular blockade to minimize the risk of coughing and the use of videolaryngoscopy, possibly with separate screen, as well as using a preloaded bougie or stylet as routine adjunct to maximize first-pass success. 2 Any AGP should be avoided, ideally including mask ventilation. Unfortunately, hypoxemia is a hallmark of COVID-19 patients requiring tracheal intubation, and patients do not tolerate the cessation of oxygen supplementation or apnea well. Conventional preoxygenation might be difficult and relatively ineffective; thus, we usually discontinue already ongoing noninvasive ventilation or continuous positive airway pressure (CPAP), turning the ventilator off and slowly removing facemask starting from the inferior edge (toward the patient's feet) to depressurize the circuit before proceeding with tracheal intubation. Should ventilation be needed, we advocate that it should be gently provided with Mapleson C (Waters; Covidien, Mirandola, Italy) circuit with a double Airway Management in COVID-19: In the Den of the Beast 

Recommendations for endotracheal intubation of COVID-19 patients

Falcetta S; and on behalf of The Società Italiana di Anestesia Analgesia Rianimazione e Terapia Intensiva (SIAARTI) Airway Research Group, and The European Airway Management Society. The Italian coronavirus disease 2019 outbreak: experiences and recommendations from clinical practice

European Centre for Disease Prevention and Control. Infection Prevention and Control for COVID-19 in Healthcare Settings

Biosafety and biohazards: understanding biosafety levels and meeting safety requirements of a biobank

Effectiveness of N95 respirators versus surgical masks against influenza: a systematic review and meta-analysis

Consensus guidelines for managing the airway in patients with COVID-19: guidelines from the Difficult Airway Society, the Association of Anaesthetists the Intensive Care Society, the faculty of intensive care medicine and the royal college of anaesthetists